Strategies for retrovirus-based correction of severe, combined immunodeficiency (SCID).

[1]  A. Schnerch,et al.  Author Correction: Direct conversion of human fibroblasts to multilineage blood progenitors , 2018, Nature.

[2]  C. von Kalle,et al.  Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Kathryn L. Parsley,et al.  Long-Term Persistence of a Polyclonal T Cell Repertoire After Gene Therapy for X-Linked Severe Combined Immunodeficiency , 2011, Science Translational Medicine.

[4]  Kathryn L. Parsley,et al.  Hematopoietic Stem Cell Gene Therapy for Adenosine Deaminase–Deficient Severe Combined Immunodeficiency Leads to Long-Term Immunological Recovery and Metabolic Correction , 2011, Science Translational Medicine.

[5]  D. Kohn,et al.  A Tale of Two SCIDs , 2011, Science Translational Medicine.

[6]  Igor Jurisica,et al.  Isolation of Single Human Hematopoietic Stem Cells Capable of Long-Term Multilineage Engraftment , 2011, Science.

[7]  Luca Biasco,et al.  Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell , 2011, EMBO molecular medicine.

[8]  Michel Sadelain,et al.  Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells , 2011, Nature Biotechnology.

[9]  A. Aiuti,et al.  Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency , 2010, Current opinion in allergy and clinical immunology.

[10]  Federico Andrea Santoni,et al.  Deciphering the Code for Retroviral Integration Target Site Selection , 2010, PLoS Comput. Biol..

[11]  F. Candotti,et al.  Mosaicism—Switch or Spectrum? , 2010, Science.

[12]  Anthony E. Boitano,et al.  Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells , 2010, Science.

[13]  A. Fischer,et al.  Immune deficiencies , infection , and systemic immune disorders Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe : Entering a new century , do we do better ? , 2010 .

[14]  M. Cavazzana‐Calvo,et al.  A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells. , 2010, Blood.

[15]  Frederic D. Bushman,et al.  Efficacy of gene therapy for X-linked severe combined immunodeficiency. , 2010, The New England journal of medicine.

[16]  A. Fischer,et al.  20 years of gene therapy for SCID , 2010, Nature Immunology.

[17]  Alessandro Aiuti,et al.  Gene therapy for immunodeficiency due to adenosine deaminase deficiency. , 2009, The New England journal of medicine.

[18]  A. Fischer,et al.  Primary immunodeficiencies: 2009 update. , 2009, The Journal of allergy and clinical immunology.

[19]  Manfred Schmidt,et al.  Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy , 2009, Science.

[20]  L. Notarangelo,et al.  How I treat ADA deficiency. , 2009, Blood.

[21]  J. Downing,et al.  Murine Leukemias with Retroviral Insertions at Lmo2 Are Predictive of the Leukemias Induced in SCID-X1 Patients Following Retroviral Gene Therapy , 2009, PLoS genetics.

[22]  A. Fischer,et al.  Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. , 2009, Blood.

[23]  U. Pannicke,et al.  Clinical and immunologic consequences of a somatic reversion in a patient with X-linked severe combined immunodeficiency. , 2008, Blood.

[24]  Christine Kinnon,et al.  Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. , 2008, The Journal of clinical investigation.

[25]  David A. Williams,et al.  Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  Luigi Naldini,et al.  Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery , 2007, Nature Biotechnology.

[27]  F. Bushman.  Retroviral integration and human gene therapy. , 2007, The Journal of clinical investigation.

[28]  Bruce Aronow,et al.  Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. , 2007, The Journal of clinical investigation.

[29]  Luca Biasco,et al.  Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. , 2007, The Journal of clinical investigation.

[30]  T. Lu,et al.  Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Weitzman,et al.  Gene therapy: twenty-first century medicine. , 2005, Annual review of biochemistry.

[32]  Kathryn L. Parsley,et al.  Failure of SCID-X1 gene therapy in older patients. , 2005, Blood.

[33]  A. Fischer,et al.  Treatment of an infant with X‐linked severe combined immunodeficiency (SCID‐X1) by gene therapy in Australia , 2005, The Medical journal of Australia.

[34]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[35]  A. Fischer,et al.  Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99 , 2003, The Lancet.

[36]  A. Mortellaro,et al.  Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.

[37]  F. Deist,et al.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.

[38]  V. Wahn,et al.  Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Roberts,et al.  Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. , 1999, The New England journal of medicine.

[40]  K. Weinberg,et al.  T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates , 1998, Nature Medicine.

[41]  J. Puck,et al.  Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency , 1996, Nature Genetics.

[42]  A. Fischer,et al.  Bone marrow gene transfer in three patients with adenosine deaminase deficiency. , 1996, Gene therapy.

[43]  S. Rosenberg,et al.  T Lymphocyte-Directed Gene Therapy for ADA− SCID: Initial Trial Results After 4 Years , 1995, Science.

[44]  Evelina Mazzolari,et al.  Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA− Immunodeficient Patients , 1995, Science.

[45]  K. Siminovitch,et al.  Atypical presentation of Wiskott-Aldrich syndrome: diagnosis in two unrelated males based on studies of maternal T cell X chromosome inactivation. , 1990, Blood.

[46]  R. Gatti,et al.  Immunological reconstitution of sex-linked lymphopenic immunological deficiency. , 1968, Lancet.

[47]  J. Stockman.  Stem-Cell Gene Therapy for the Wiskott–Aldrich Syndrome , 2012 .

[48]  M. Dinauer,et al.  Gene therapy of chronic granulomatous disease: the engraftment dilemma. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  L. Scobie,et al.  A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  F. Rieux-Laucat,et al.  Long-term immune reconstitution in RAG-1-deficient mice treated by retroviral gene therapy: a balance between efficiency and toxicity. , 2006, Blood.

[51]  W. Leonard,et al.  The molecular basis of X-linked severe combined immunodeficiency: defective cytokine receptor signaling. , 1996, Annual review of medicine.

[52]  B. Bainbridge,et al.  Genetics , 1981, Experientia.